Anions as Triggers in Controlled Release Protocols from Mesoporous Silica Nanoparticles Functionalized with Macrocyclic Copper(II) Complexes

Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold

Adenosine triphosphate (ATP)-competitive inhibitors of the epidermal growth factor receptor (EGFR) have provided a significant improvement in the disease outcome of nonsmall cell lung cancer (NSCLC). Unfortunately, some marketed drugs affect a transient beneficial response in EGFR mutant NSCLC patients. We reported a series of potential EGFR inhibitors through incorporation of macrocyclic polyamine into 4-anilinoquinazoline scaffold. It is expected that anilinoquinazoline part effectively bind to EGFR domain, while ATP molecules are captured by a macrocyclic polyamine moiety. In vitro experiments exhibited that most of tested compounds suppressed tumor cell proliferation more strongly than Gefitinib and Lapatinib (dual inhibitor of EGFR/HER2) as controls. In kinase assays, the compound 1f showed excellent dual inhibition activity toward EGFR^WT (IC₅₀ = 1.4 nM) and HER2 (IC₅₀ = 2.1 nM). In vivo pharmacology evaluation of 1f showed significant antitumor activity (TGI = 44.2%) in A549 xenografts mice. The current work provided a feasible solution to optimize anilinoquinazoline-based inhibitors.

Sustained Protein Release from a Core-Shell Drug Carrier System Comprised of Mesoporous Nanoparticles and an Injectable Hydrogel

The manufacture of a biocompatible carrier for controlled delivery of bioactive compounds is described. This carrier is composed of a mesoporous silica nanoparticle as core that is homogenously distributed in an injectable hydrogel. For the synthesis of nanoparticles, a one step sol-gel method is developed to produce pores with the range of 100 nm. BMP2 and Fluorescein-conjugated bovine serum albumin is used as proteinaceous agents for measuring release, and is loaded into mesoporous silica nanoparticles at the optimum conditions of 48 h incubation period using 1:10 ratio of protein to nanoparticles. The release of proteins from either mesoporous nanoparticles or hydrogel individually involves a burst release stage, however the release from the core/shell carrier designed in this study follows a zero order kinetic. In summary, this biomaterial may be favorable for delivery of bioactive compounds such as BMP2 for a range of applications including bone tissue regeneration.

NO2-controlled cargo delivery from gated silica mesoporous nanoparticles

Cargo delivery from mesoporous silica nanoparticles loaded with sulforhodamine B and capped with a difluoroboron-dipyrromethene (BODIPY) derivative was triggered by a NO₂-induced oxidative process.

Acetylcholinesterase-capped Mesoporous Silica Nanoparticles Controlled by the Presence of Inhibitors

Two different acetylcholinesterase (AChE)-capped mesoporous silica nanoparticles (MSNs), S1-AChE and S2-AChE, were prepared and characterized. MSNs were loaded with rhodamine B and the external surface was functionalized with either pyridostigmine derivative P1 (to yield solid S1) or neostigmine derivative P2 (to obtain S2). The final capped materials were obtained by coordinating grafted P1 or P2 with AChE's active sites (to give S1-AChE and S2-AChE, respectively). Both materials were able to release rhodamine B in the presence of diisopropylfluorophosphate (DFP) or neostigmine in a concentration-dependent manner via the competitive displacement of AChE through DFP and neostigmine coordination with the AChE's active sites. The responses of S1-AChE and S2-AChE were also tested with other enzyme inhibitors and substrates. These studies suggest that S1-AChE nanoparticles can be used for the selective detection of nerve agent simulant DFP and paraoxon.